AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10551571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-frequency (2- and 100-Hz) TENS
Number of subjects: 100
Study 8896540 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka/SB Bio)
Number of subjects: 1400
Study 1803786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxin 0.125 mg
Number of subjects: 20
Study 1803786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxicaps 0.1 mg
Number of subjects: 20
Study 1803786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxin 0.25 mg
Number of subjects: 20
Study 1803786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxicaps 0.2 mg
Number of subjects: 20
Study 6340512 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 124
Study 6340512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 6340512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with cystoid macular edema)
Number of subjects: 124
Study 6340512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (without cystoid macular edema)
Number of subjects: 124
Study 31973959 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Glasses (VG)
Number of subjects: 0
Study 31973959 — intervention group
Group type: COMPARATOR
Intervention: Portable Multimedia Player (PMP)
Number of subjects: 0
Study 30414225 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 240
Study 30414225 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 240
Study 27583797 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mW/cm ultraviolet A irradiation for 120 seconds
Number of subjects: 23
Study 27583797 — intervention group
Group type: COMPARATOR
Intervention: 18 mW/cm ultraviolet A irradiation for 180 seconds
Number of subjects: 23
Study 26037245 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (titrated to 16 mg/day)
Number of subjects: 41
Study 26037245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24245604 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure text message visualisation tasks
Number of subjects: 0
Study 24245604 — intervention group
Group type: COMPARATOR
Intervention: Neutral text message visualisation tasks
Number of subjects: 0
Study 21725919 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 1706
Study 21725919 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS)
Number of subjects: 1706
Study 21725919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for other known and potential risk factors
Number of subjects: 1706
Study 21725919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for creatinine
Number of subjects: 1706
Study 19214951 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy
Number of subjects: 124
Study 19214951 — intervention group
Group type: COMPARATOR
Intervention: PDT with Photofrin
Number of subjects: 124
Study 17541103 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 2177
Study 17541103 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 2177
Study 15165530 — intervention group
Group type: EXPERIMENTAL
Intervention: autoCPAP
Number of subjects: 22
Study 15165530 — intervention group
Group type: COMPARATOR
Intervention: fixed CPAP
Number of subjects: 22
Study 11753021 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 11753021 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 9612619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil based chemotherapy
Number of subjects: 0
Study 9612619 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study 7751115 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-reinforced membrane and osseointegrated implants
Number of subjects: 5
Study 2661788 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.1 mg/kg four times a day, 1/2 hour before feeding for 1 week
Number of subjects: 30
Study 2661788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2661788 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 30
Study 29931294 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless piezocision‐assisted corticotomy
Number of subjects: 36
Study 29931294 — intervention group
Group type: COMPARATOR
Intervention: Traditional orthodontic treatment (Control)
Number of subjects: 36
Study 28288057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection (ME with LLND)
Number of subjects: 701
Study 28288057 — intervention group
Group type: COMPARATOR
Intervention: Mesorectal excision alone (ME alone)
Number of subjects: 701
Study 25713025 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin use (moderate versus nonregular use)
Number of subjects: 1819
Study 25713025 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen use
Number of subjects: 1819
Study 23414206 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Cancer Recovery (MBCR) program
Number of subjects: 64
Study 23414206 — intervention group
Group type: COMPARATOR
Intervention: Waiting for the next available group (Control)
Number of subjects: 64
Study 21504893 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs9350 in Exonuclease-1 (EXO1)
Number of subjects: 2836
Study 21504893 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs17503908 in ataxia telangiectasia mutated (ATM)
Number of subjects: 2836
Study 18355138 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic insertion of Double-J stents for 4 weeks
Number of subjects: 195
Study 18355138 — intervention group
Group type: COMPARATOR
Intervention: Stentless (control group)
Number of subjects: 195
Study 16507028 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment programme for depression
Number of subjects: 34
Study 16507028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 14552511 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentary about schizophrenia
Number of subjects: 163
Study 14552511 — intervention group
Group type: COMPARATOR
Intervention: No documentary film
Number of subjects: 163
Study 14552511 — intervention group
Group type: COMPARATOR
Intervention: Documentary about polar bears
Number of subjects: 163
Study 14552511 — intervention group
Group type: COMPARATOR
Intervention: Documentary about fears of being overweight
Number of subjects: 163
Study 10945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.1 mg/d)
Number of subjects: 261
Study 10945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.05 mg/d)
Number of subjects: 261
Study 10945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.0375 mg/d)
Number of subjects: 261
Study 10945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.025 mg/d)
Number of subjects: 261
Study 10945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (all doses)
Number of subjects: 261
Study 10945511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 8837408 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects attending to the predictive aspect of FOK definitions
Number of subjects: 0
Study 8837408 — intervention group
Group type: COMPARATOR
Intervention: Subjects assessing what they believed they knew
Number of subjects: 0
Study 1308130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control with a step-up regimen including insulin alone or insulin/glipizide combinations
Number of subjects: 151
Study 1308130 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy group with insulin
Number of subjects: 151
Study 1308130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intensive and standard control)
Number of subjects: 151
Study 6363659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone administration
Number of subjects: 739
Study 6363659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 3086948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine carbonate (1% solution)
Number of subjects: 30
Study 3086948 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine hydrochloride
Number of subjects: 30
Study 29266879 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100-200 mg twice daily)
Number of subjects: 24081
Study 29266879 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600-800 mg 3 times daily)
Number of subjects: 24081
Study 29266879 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (375-500 mg twice daily)
Number of subjects: 24081
Study 28915919 — intervention group
Group type: EXPERIMENTAL
Intervention: Project LifeSkills intervention
Number of subjects: 0
Study 28915919 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 0
Study 28915919 — intervention group
Group type: COMPARATOR
Intervention: Diet and nutrition time- and attention-matched control
Number of subjects: 0
Study 25936817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment FDG-PET (PET arm)
Number of subjects: 129
Study 25936817 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment FDG-PET)
Number of subjects: 129
Study 25936817 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival (both arms)
Number of subjects: 129
Study 25936817 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from extrapelvic metastasis (both arms)
Number of subjects: 129
Study 23715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation 4 times a day for 6 days
Number of subjects: 16
Study 23715246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20656831 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reading with CAD
Number of subjects: 28204
Study 20656831 — intervention group
Group type: EXPERIMENTAL
Intervention: Double reading
Number of subjects: 28204
Study 20656831 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD
Number of subjects: 28204
Study 18379395 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbed (Akva)
Number of subjects: 141
Study 18379395 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-conforming foam mattress (Tempur)
Number of subjects: 141
Study 18379395 — intervention group
Group type: COMPARATOR
Intervention: Hard mattress (Innovation Futon)
Number of subjects: 141
Study 16685087 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable interference screw (PLLA group)
Number of subjects: 77
Study 16685087 — intervention group
Group type: COMPARATOR
Intervention: Metal interference screw (metal group)
Number of subjects: 77
Study 12580983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50 mg
Number of subjects: 172
Study 12580983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 172
Study 12580983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 11081541 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 0
Study 11081541 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing rate during yoga
Number of subjects: 0
Study 8781000 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored nutrition intervention
Number of subjects: 347
Study 8781000 — intervention group
Group type: COMPARATOR
Intervention: General nutrition information
Number of subjects: 347
Study 1736868 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal essential medium at 31 degrees C
Number of subjects: 28
Study 1736868 — intervention group
Group type: COMPARATOR
Intervention: McCarey-Kaufman medium at 4 degrees C
Number of subjects: 28
Study 6430337 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP
Number of subjects: 0
Study 6430337 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0
Study 6430337 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 31448533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (Gp-L)
Number of subjects: 98
Study 31448533 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Gp-NL)
Number of subjects: 98
Study 31448533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose responders
Number of subjects: 98
Study 31448533 — intervention group
Group type: EXPERIMENTAL
Intervention: MHE patients
Number of subjects: 98
Study 30327358 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia
Number of subjects: 23
Study 30327358 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoglycemia
Number of subjects: 23
Study 30327358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp
Number of subjects: 23
Study 29231522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of moxibustion along the governor vessel and the conception vessel with salazosulfapyridine (SASP)
Number of subjects: 62
Study 29231522 — intervention group
Group type: COMPARATOR
Intervention: Routine moxibustion therapy
Number of subjects: 62
Study 25371536 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS postdilated with SeQuent Please DEB
Number of subjects: 90
Study 25371536 — intervention group
Group type: COMPARATOR
Intervention: XIENCE V DES
Number of subjects: 90
Study 23210421 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm fluoride mouthwash
Number of subjects: 30
Study 23210421 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 ppm fluoride mouthwash
Number of subjects: 30
Study 23210421 — intervention group
Group type: COMPARATOR
Intervention: No rinse
Number of subjects: 30
Study 20179727 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosphingosine (PS) 500 mg twice daily
Number of subjects: 12
Study 20179727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 18392052 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up vaccination
Number of subjects: 24510
Study 16382257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 11638
Study 16382257 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 11638
Study 12487780 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')(2) FRaMon 0.2 mg/kg
Number of subjects: 58
Study 12487780 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')(2) FRaMon 0.25 mg/kg
Number of subjects: 58
Study 12487780 — intervention group
Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 58
Study 12487780 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')(2) FRaMon
Number of subjects: 58
Study 9437382 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen catheters coated with chlorhexidine and silver sulfadiazine (CSS)
Number of subjects: 308
Study 9437382 — intervention group
Group type: COMPARATOR
Intervention: Uncoated triple-lumen catheters
Number of subjects: 308
Study 7865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 5.7, 11.4, and 17.1 pmol kg‐1 min‐1 CDD/ANP‐99‐126
Number of subjects: 0
Study 7865980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CDD/ANP‐99‐126
Number of subjects: 0
Study 2673438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly three day course with adriamycin (ADM), cyclophosphamide (CPM), vindesine (VDS) and 5 fluoro‐uracil (5 FU)
Number of subjects: 94
Study 2673438 — intervention group
Group type: COMPARATOR
Intervention: Fractionated schedule with 4 injections of ADM, CPM, VDS and continuous infusion of 5 FU over 10 days
Number of subjects: 94
Study 338104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen (piperazine oestrone sulphate)
Number of subjects: 34
Study 338104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving abortions (repeat abortions)
Number of subjects: 2370
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-use of contraception
Number of subjects: 2370
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Having children
Number of subjects: 2370
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in a middle-developed region
Number of subjects: 2370
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in a relatively poor region
Number of subjects: 2370
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Using contraception (condom use)
Number of subjects: 2370
Study 30841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation as a student
Number of subjects: 2370
Study 29027108 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3‐ITD mutation
Number of subjects: 103
Study 29027108 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutation
Number of subjects: 103
Study 29027108 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutations in absence of FLT3‐ITD
Number of subjects: 103
Study 29027108 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3‐ITD in absence of NPM1 mutations
Number of subjects: 103
Study 29027108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 103
Study 29027108 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 103
Study 29027108 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OS among AYAs, children, and older adults
Number of subjects: 103
Study 26624965 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping Interval Training (JIT)
Number of subjects: 18
Study 24795251 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 664
Study 24795251 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 664
Study 24795251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 22392354 — intervention group
Group type: EXPERIMENTAL
Intervention: Desarda technique (D)
Number of subjects: 208
Study 22392354 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique (L)
Number of subjects: 208
Study 19672152 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus LY293111 (LY) 600 mg twice daily
Number of subjects: 0
Study 19672152 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus placebo
Number of subjects: 0
Study 17502466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (2, 4, or 6 mg during 24 hours for 24 weeks)
Number of subjects: 277
Study 17502466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 17502466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system
Number of subjects: 277
Study 15031343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol treatment
Number of subjects: 36
Study 15031343 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 12153335 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 80 or 160 mg/day
Number of subjects: 300
Study 12153335 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 160 mg/day
Number of subjects: 300
Study 12153335 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 40 to 160 mg/day
Number of subjects: 300
Study 12153335 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 300
Study 12153335 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ziprasidone
Number of subjects: 300
Study 12153335 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral ziprasidone treatment
Number of subjects: 300
Study 9222908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar L incision
Number of subjects: 47
Study 9222908 — intervention group
Group type: COMPARATOR
Intervention: Standard incision
Number of subjects: 47
Study 7702784 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron plus metoclopramide
Number of subjects: 66
Study 7702784 — intervention group
Group type: COMPARATOR
Intervention: ondansetron alone
Number of subjects: 66
Study 3665218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISMN) 40 mg
Number of subjects: 20
Study 3665218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 20
Study 30357437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose, target plasma level 100 ng/ml)
Number of subjects: 15
Study 30357437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28236583 — intervention group
Group type: COMPARATOR
Intervention: BEACOPPescalated
Number of subjects: 440
Study 28236583 — intervention group
Group type: EXPERIMENTAL
Intervention: R-BEACOPPescalated
Number of subjects: 440
Study 26302337 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP/NLX) and counseling for 12 weeks
Number of subjects: 149
Study 23674608 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rifampicin
Number of subjects: 24
Study 23674608 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rifampicin
Number of subjects: 24
Study 23674608 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rifampicin
Number of subjects: 24
Study 19767711 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric drug therapy in addition to topical corticosteroids
Number of subjects: 46
Study 19767711 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids only (Control)
Number of subjects: 46
Study 19767711 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric drug therapy
Number of subjects: 46
Study 18355656 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 400
Study 18355656 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 400
Study 16553140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi chuan (TCC) 3 times/wk for 12 weeks
Number of subjects: 21
Study 16553140 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial therapy (PST; physical activity control) 3 times/wk for 12 weeks
Number of subjects: 21